Enhancing the A in SAFE for Trachoma
Trachoma
About this trial
This is an interventional treatment trial for Trachoma focused on measuring Mass drug administration, South Sudan, Trachoma
Eligibility Criteria
Inclusion Criteria for Villages: The village must be located in a district eligible for annual MDA with azithromycin under WHO treatment guidelines. The village representatives' consent to participation in the study. Individual consent will also be obtained for each individual within the study. Inclusion Criteria for Children in Enhanced MDA Strategy 1: Children aged 6 months to 9 years of age Consent for child inclusion is obtained by the parent/guardian and adequate provisions are made to solicit assent from the child. Exclusion Criteria: none
Sites / Locations
- Ministry of Health Republic of South SudanRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Routine Community-wide MDA followed by Two Additional Rounds of Treatment for Children
Routine Community-wide MDA followed by a Second Community-wide MDA
Standard-of-Care Annual MDA
The enhanced MDA Strategy 1 consists of a routine community-wide MDA followed by two additional rounds targeted to children age 6 months to 9 years. The additional rounds of treatment will occur 2 weeks apart and will begin 1 week after the community-wide MDA.
The enhanced MDA Strategy 2 consist of a routine community-wide MDA followed by a second community-wide MDA approximately 6-8 months later. The timing of the second MDA will depend on local conditions and logistical concerns.
Programmatic Control Comparator data for the standard-of-care annual MDA will come from the MDA conducted in 2022 in a random selection of 15 non-study villages.